Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

Annual General Meeting. Collectively, they bring to the OncoGenex board immense executive leadership experience in late stage clinical development, commercialization and business development for pharmaceuticals and biologics. - The Company was awarded the Biotech Company of the Year award by BIOTECanada at the BIO 2010 Convention.

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the first quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase III trials
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... CHENGDU, China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., ... supplier of,modernized traditional Chinese medicine ("TCM") based in Chengdu, ... Chinese State Food and Drug,Administration (SFDA) to produce Sanqi ... Z20093512) and Yinqiao Jiedu Tablets in,dosage form of 0.5 ...
... Diagnostics Inc., (TSX: SDI), a company focused on bringing ... sepsis, today announced its financial results for the second ... results of the EUPHAS trial in Italy were published ... findings showed that the Toraymyxin(TM) cartridge significantly reduced mortality ...
... ... on the 2009 Inc. 5000 , ... Boston, MA (PRWEB) August 13, 2009 -- Inc. magazine announced on ... Technology Corporation (MTC), a diversified technology solutions company and a leader in web-database solutions, ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3Spectral announces second quarter 2009 results 2Spectral announces second quarter 2009 results 3Spectral announces second quarter 2009 results 4Spectral announces second quarter 2009 results 5Spectral announces second quarter 2009 results 6Spectral announces second quarter 2009 results 7Spectral announces second quarter 2009 results 8Massachusetts Technology Corporation Named to Inc. 5000 List of Fastest Growing Private Companies 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... and security consultant, Apollo Robbins for the ... wallet.  Apollo Robbins will ... th , 2015, demonstrating some of his famous theft ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... bigger may be better. That,s the main finding from ... lungs lead to improved survival following lung transplants, particularly ... United States height is used as a surrogate for ... assistant professor in internal medicine at the UI, and ...
... that rubber slat mats could improve swine health. In a ... researchers in Europe studied how different types of flooring affects ... to the researchers, flooring is one of the main factors ... problems can be caused by joint injuries or by circulatory ...
... Nutritional Science (IUNS) 20th Congress of Nutrition, taking place ... nutrition experts from around the world to discuss the ... on 19 September, a Symposium on "Maintaining health with ... of metabolic syndrome, CVD, obesity and sarcopenia" will present ...
Cached Biology News:Bigger lungs may be better for transplants 2Rubber slat mats could improve animal well-being 2'Exploring the Latest Evidence of Dairy's Contribution to Nutrition at IUNS Satellite Symposium' 2'Exploring the Latest Evidence of Dairy's Contribution to Nutrition at IUNS Satellite Symposium' 3
Request Info...
2 ml SmartScan Racks...
... Immunogen: Partially purified chicken intestinal ... vitamin D receptor (VDR) from human, ... fish tissues. This antibody does ... receptors. MA1-710 detects both the ...
... of 2D polyacrylamide gel electrophoresis (2D-PAGE) with ... a core technology platform for proteomic analysis. ... complex samples limited only in the dynamic ... large proteins. Quantitative image based analysis of ...
Biology Products: